Worg continues to expand the scope of its proprietary PCFiT platform by performing R&D in other allergens of global or regional importance. Multiple research programs are currently underway. The final goal is to have a broad menu of immunotherapy products for the vast majority of allergy sufferers worldwide.

Worg is also expanding the indications beyond allergy with undisclosed projects.